Cancer BiologyClinical Cancer ResearchPeer-reviewed
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
Alexander J. Pfeil, Tom Zhang, Ryan Cheng…·Romel Somwar
This study identifies RRASQ87L and RRAS2Q72L mutations as recurrent oncogenic drivers in lung cancer and shows sensitivity to the pan-RAS inhibitor RMC-6236.
3 citationstop 2%